ARWR VS AXSM Stock Comparison

Performance

ARWR
10/100

ARWR returned -18.45% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

AXSM
100/100

AXSM returned 45.76% in the last 12 months. Based on SPY's performance of -21.15%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

ARWR
63/100

4 analysts offer 12-month price targets for ARWR. Together, they have an average target of 63.86, the most optimistic target put ARWR at 90 within 12-months and the most pessimistic has ARWR at 31.

AXSM
100/100

2 analysts offer 12-month price targets for AXSM. Together, they have an average target of 81, the most optimistic target put AXSM at 150 within 12-months and the most pessimistic has AXSM at 25.

Technicals

ARWR
64/100

ARWR receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

AXSM
11/100

AXSM receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

ARWR
10/100

ARWR has missed earnings 16 times in the last 20 quarters.

AXSM
10/100

AXSM has missed earnings 7 times in the last 20 quarters.

Profit

ARWR
24/100

Out of the last 20 quarters, ARWR has had 6 profitable quarters and has increased their profits year over year on 2 of them.

AXSM
10/100

Out of the last 20 quarters, AXSM has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

ARWR
50/100

ARWR has had a higher than average amount of volatility over the last 12 months giving it a score of 50 of 100.

AXSM
53/100

AXSM has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

Sentiment

ARWR

"Sentiment" not found for ARWR

AXSM
73/100

AXSM had a bullish sentiment score of 72.99% across Twitter and StockTwits over the last 12 months. It had an average of 59.44 posts, 422.00 comments, and 1,188.34 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

Arrowhead Research Corporation Summary

Nasdaq / ARWR

Healthcare

Biotechnology

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Axsome Therapeutics, Inc Summary

Nasdaq / AXSM

Healthcare

Biotechnology

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Power up your portfolio